

DAFTAR PUSTAKA

- Abolhassani, H., Mohammadzadeh Honarvar, N., Mosby, T. T., & Mahmoudi, M. (2020). Nutrition, immunity, and cancers. *Cancer Immunology: A Translational Medicine Context*, 533–544.
- Aguilar-Cazares, D., Chavez-Dominguez, R., Marroquin-Muciño, M., Perez-Medina, M., Benito-Lopez, J. J., Camarena, A., Rumbo-Nava, U., & Lopez-Gonzalez, J. S. (2022). The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. *Frontiers in Endocrinology*, 13, 929572.
- Agusweni, T., Dewi, Y.I. and Erwin (2020), ‘Gambaran Faktor Risiko Insiden Kanker Ovarium di RSUD Arifin Achmad Provinsi Riau’, *Jurnal Ners Indonesia*, 11(1), pp. 36–50.
- Ahmat Amin, M. K. B., Shimizu, A., & Ogita, H. (2019). The pivotal roles of the epithelial membrane protein family in cancer invasiveness and metastasis. *Cancers*, 11(11), 1620.
- Akter, S., Rahman, Md. A., Hasan, M. N., Akhter, H., Noor, P., Islam, R., Shin, Y., Rahman, Md. H., Gazi, Md. S., Huda, M. N., Nam, N. M., Chung, J., Han, S., Kim, B., Kang, I., Ha, J., Choe, W., Choi, T. G., & Kim, S. S. (2022). Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. *Cells*, 11(4), 650. <https://doi.org/10.3390/cells11040650>
- Armstrong D. K., Alvarez R. D., Bakkum-Gamez J. N., Barroilhet L., Kian Behbakht, Berchuck A.. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. Journal of The National Comprehensive Cancer Network. 2019 Aug 1;17(8):896–909.
- Angeli, D., Salvi, S., & Tedaldi, G. (2020). Genetic predisposition to breast and ovarian cancers: How many and which genes to test? *International Journal of Molecular Sciences*, 21(3), 1128.
- Aqilla, S., Harsono, A.B. and Agustina, H. (2022) ‘Gambaran Klinis dan Histopatologi Kanker Ovarium di RSUP Dr. Hasan Sadikin Bandung Tahun 2019–2020’, *Indonesian Journal of Obstetrics & Gynecology Science*, 5(1), pp. 127–135.
- Arora, N., Talhouk, A., McAlpine, J. N., Law, M. R., & Hanley, G. E. (2018). Long-term mortality among women with epithelial ovarian cancer: A population-based study in British Columbia, Canada. *BMC Cancer*, 18(1), 1039. <https://doi.org/10.1186/s12885-018-4970-9>
- Azam, F., Latif, M. F., Farooq, A., Tirmazy, S. H., AlShahrani, S., Bashir, S., & Bukhari, N. (2019). Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. *Case Reports in Oncology*, 12(3), 728–736. <https://doi.org/10.1159/000503095>
- Blanquicett, C., Cohen, J. B., Flowers, C., & Johnson II, T. (2019). The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient. *Oncology (08909091)*, 33(11).

- Bohara, S., Jain, S., Khurana, N., Shangpliang, D. M., Agarwal, S., & Gandhi, G. (2018). Intraoperative cytology of ovarian neoplasms with an attempt to grade epithelial tumors. *Journal of Cytology*, 35(1), 1.
- Braicu, Buse, Busuioc, Drula, Gulei, Raduly, Rusu, Irimie, Atanasov, Slaby, Ionescu, & Berindan-Neagoe. (2019). A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. *Cancers*, 11(10), 1618. <https://doi.org/10.3390/cancers11101618>
- Budiana, B., Mahendra, B., Wiradnyana, P., Darmayasa, D., Marta, F., & Suwanpramana, S. (2023). C-Reactive Protein/Albumin (Crp/Alb) Ratio as a Predictor of Ovarian Cancer. *Jurnal Health Sains*, 4(5), 79–90.
- Budiana, I. N. G., Angelina, M., & Pemayun, T. G. A. (2019). Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *Journal of the Turkish-German Gynecological Association*, 20(1), 47–54. <https://doi.org/10.4274/jtgga.galenos.2018.2018.0119>
- Bulun, S. E., Wan, Y., & Matei, D. (2019). Epithelial mutations in endometriosis: Link to ovarian cancer. *Endocrinology*, 160(3), 626–638.
- Cano, D. G. S., Flores, H. A. C., De los Santos Farrera, O., Martinez, N. B. G., Céspedes, D. S., De los Santos-Farrera, O., & Guzman, N. (2021). Sensitivity and specificity of ultrasonography using Ovarian-Adnexal Reporting and Data System classification versus pathology findings for ovarian cancer. *Cureus*, 13(9).
- Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R. (2019). Ovarian cancer: Current status and strategies for improving therapeutic outcomes. *Cancer Medicine*, 8(16), 7018–7031.
- Chang, L.-C., Huang, C.-F., Lai, M.-S., Shen, L.-J., Wu, F.-L. L., & Cheng, W.-F. (2018). Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS One*, 13(3), e0194993.
- Chapman-Davis, E., Zhou, Z. N., Fields, J. C., Frey, M. K., Jordan, B., Sapra, K. J., Chatterjee-Paer, S., Carlson, A. D., & Holcomb, K. M. (2021). Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center. *Journal of General Internal Medicine*, 36, 35–42.
- Chase, D. M., Mahajan, A., Scott, D. A., Hawkins, N., & Kalilani, L. (2023). Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review. *International Journal of Gynecologic Cancer*, 33(10).
- Chase, D.M., Mahajan, A., Scott, D.A., Hawkins, N. and Kalilani, L., 2023. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review. *International Journal of Gynecologic Cancer*, 33(10).
- Chaudhry, S., Thomas, S. N., & Simmons Jr., G. E. (2022). Targeting lipid metabolism in the treatment of ovarian cancer. *Oncotarget*, 13(1), 768–783. <https://doi.org/10.18632/oncotarget.28241>
- Chen, T., Jiang, W. and He, G. (2021) ‘Effect of family enteral nutrition on nutritional status in elderly patients with esophageal carcinoma after minimally invasive radical surgery: a randomized trial’, *Annals of Palliative Medicine*, 10(6), pp. 6760–6767. doi:10.21037/apm-21-1219.

- Chen, Y., Huang, B., Zheng, J., & He, F. (2023) 'Prediction study of prognostic nutrition index on the quality of life of patients with cervical cancer undergoing radiotherapy and chemotherapy', *PeerJ*, 11, p. e15442. doi:10.7717/peerj.15442.
- Cole, C. L., Kleckner, I. R., Jatoti, A., Schwarz, E. M., & Dunne, R. F. (2018). The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention. *JCSM Clinical Reports*, 3(2), 1–19. <https://doi.org/10.17987/jcsm-cr.v3i2.65>
- Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018). Advances in ovarian cancer therapy. *Cancer Chemotherapy and Pharmacology*, 81, 17–38.
- Dai, Y., Liu, M., Lei, I., & Lu, S. (2020) 'Prognostic significance of preoperative prognostic nutritional index in ovarian cancer', *Medicine*, 99(38), p. e21840. doi:10.1097/MD.00000000000021840.
- Damayanti, I.N., Yulianti, I. and Kusumastuti, E.H. (2016) 'Three years survival rate of epithelial ovarian cancer patients in Dr. Kariadi Hospital, Semarang, Central Java', *Materia Obstetrics & Gynecology*, 24(3), pp. 100–104.
- Delgado, A., & Guddati, A. K. (2021). Clinical endpoints in oncology-a primer. *American journal of cancer research*, 11(4), 1121.
- Demir, A. (2020). The Relationship Between the Prognostic Nutritional Index and Overall Survival in Elderly Patients with Epithelial Ovarian Cancer. *Eurasian Journal of Medical Investigation*. <https://doi.org/10.14744/ejmi.2020.30288>
- Deng, K., Yang, C., Tan, Q., Song, W., Lu, M., Zhao, W., Lou, G., Li, Z., Li, K., & Hou, Y. (2018). Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. *Gynecologic Oncology*, 150(3), 460–465.
- Di Lorenzo, G., Ricci, G., Severini, G. M., Romano, F., & Biffi, S. (2018). Imaging and therapy of ovarian cancer: Clinical application of nanoparticles and future perspectives. *Theranostics*, 8(16), 4279.
- Ding, P., Lv, J., Sun, C., Chen, S., Yang, P., Tian, Y., Zhou, Q., Guo, H., Liu, Y., & Zhao, Q. (2022). Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for sarcopenia in patients with locally advanced gastric cancer. *Frontiers in Nutrition*, 9, 981533. <https://doi.org/10.3389/fnut.2022.981533>
- Dioguardi, F. S., Chen-Scarabelli, C., Pasini, E., Corsetti, G., & M Scarabelli, T. (2022). Diet, Muscle Protein Synthesis and Autophagy Relationships in Cancer: An Attempt to Understand Where Are We Going, and Why. *Advances in Nutrition and Food Science*, 2022(04). <https://doi.org/10.37722/ANAFS.2022401>
- Doshi, A. S., & Asrani, K. H. (2022). Innate and adaptive immunity in cancer. In *Cancer Immunology and Immunotherapy* (pp. 19–61). Elsevier.
- Dou, Y., Jiang, X., Xie, H., He, J., & Xiao, S. (2019). The Jun N-terminal kinases signaling pathway plays a “seesaw” role in ovarian carcinoma: A

- molecular aspect. *Journal of Ovarian Research*, 12(1), 99.
<https://doi.org/10.1186/s13048-019-0573-6>
- Drakes, M. L., & Stiff, P. J. (2018). Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment. *Cancers*, 10(9), 302.
<https://doi.org/10.3390/cancers10090302>
- Efron, P. A., Mohr, A. M., Bihorac, A., Horiguchi, H., Hollen, M. K., Segal, M. S., Baker, H. V., Leeuwenburgh, C., Moldawer, L. L., Moore, F. A., & Brakenridge, S. C. (2018). Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery. *Surgery*, 164(2), 178–184.
<https://doi.org/10.1016/j.surg.2018.04.011>
- Feng, Z., Wen, H., Ju, X., Bi, R., Chen, X., Yang, W., & Wu, X. (2018). The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. *BMC Cancer*, 18(1), 883.
<https://doi.org/10.1186/s12885-018-4732-8>
- Flaum, N., Crosbie, E. J., Edmondson, R. J., Smith, M. J., & Evans, D. G. (2020). Epithelial ovarian cancer risk: A review of the current genetic landscape. *Clinical Genetics*, 97(1), 54–63.
- Fuchs-Tarlovsky, V., Castillo Pineda, J. C., Rodriguez Veintimilla, D., Calvo Higuera, I., Grijalva Guerrero, P., Gomez Garcia, A., Frias-Toral, E., & Santana Porben, S. (2022). Cancer-related malnutrition: Epidemiological results from the Latin American Study of malnutrition in the oncology practice. *Nutrition and Cancer*, 74(7), 2479–2488.
- Gaitskell, K., Hermon, C., Barnes, I., Pirie, K., Floud, S., Green, J., Beral, v., & Reeves, G. K. (2022). ‘Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study’, *Cancer Epidemiology*, 76, p. 102074. doi:10.1016/j.canep.2021.102074.
- Gaitskell, K., Green, J., Pirie, K., Barnes, I., Hermon, C., Reeves, G. K., Valerie B. & Million Women Study Collaborators. (2018). Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. *International journal of cancer*, 142(2), 281–289.
- Gaona-Luviano, P., Medina-Gaona, L. A., & Magaña-Pérez, K. (2020). Epidemiology of ovarian cancer. *Chinese Clinical Oncology*, 9(4), 47–47.
<https://doi.org/10.21037/cco-20-34>
- Gardner, A. B., Charo, L. M., Mann, A. K., Kapp, D. S., Eskander, R. N., & Chan, J. K. (2020). Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: Most common locations and outcomes. *Clinical & Experimental Metastasis*, 37(1), 107–113.
<https://doi.org/10.1007/s10585-019-10007-0>
- Ge, L.-N., & Wang, F. (2018). Prognostic significance of preoperative serum albumin in epithelial ovarian cancer patients: A systematic review and dose–response meta-analysis of observational studies. *Cancer Management and Research*, Volume 10, 815–825.
<https://doi.org/10.2147/CMAR.S161876>

- Ghoneum, A., Afify, H., Salih, Z., Kelly, M., & Said, N. (2018). Role of tumor microenvironment in ovarian cancer pathobiology. *Oncotarget*, 9(32), 22832–22849. <https://doi.org/10.18632/oncotarget.25126>
- Gori, S., Barberis, M., Bella, M. A., Buttitta, F., Capoluongo, E., Carrera, P., Colombo, N., Cortesi, L., Genuardi, M., & Gion, M. (2019). Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. *Critical Reviews in Oncology/Hematology*, 140, 67–72.
- Han, C. Y., Patten, D. A., Richardson, R. B., Harper, M.-E., & Tsang, B. K. (2018). Tumor metabolism regulating chemosensitivity in ovarian cancer. *Genes & Cancer*, 9(5–6), 155–175. <https://doi.org/10.18632/genesandcancer.176>
- Harrington, B. S., & Annunziata, C. M. (2019). NF-κB Signaling in Ovarian Cancer. *Cancers*, 11(8), 1182. <https://doi.org/10.3390/cancers11081182>
- Hawkes, N. (2019). Cancer survival data emphasise importance of early diagnosis. *BMJ*, 1408. <https://doi.org/10.1136/bmj.1408>
- Hawkins, R. B., Raymond, S. L., Stortz, J. A., Horiguchi, H., Brakenridge, S. C., Gardner, A., Efron, P. A., Bihorac, A., Segal, M., Moore, F. A., & Moldawer, L. L. (2018). Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome. *Frontiers in Immunology*, 9, 1511. <https://doi.org/10.3389/fimmu.2018.01511>
- Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018a). Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force. In *Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force [Internet]*. Agency for Healthcare Research and Quality (US). <https://www.ncbi.nlm.nih.gov/books/NBK493401/>
- Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018b). Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*, 319(6), 595. <https://doi.org/10.1001/jama.2017.21421>
- Ho, C. Y., Ibrahim, Z., Abu Zaid, Z., Mat Daud, Z. 'Azuan, & Md Yusop, N. B. (2021). Clinical malnutrition predictive model among gynecologic cancer patients prior to elective operation: A cross-sectional study. *Clinical Nutrition*, 40(6), 4373–4379. <https://doi.org/10.1016/j.clnu.2021.01.008>
- Horiguchi, H., Loftus, T. J., Hawkins, R. B., Raymond, S. L., Stortz, J. A., Hollen, M. K., Weiss, B. P., Miller, E. S., Bihorac, A., Larson, S. D., Mohr, A. M., Brakenridge, S. C., Tsujimoto, H., Ueno, H., Moore, F. A., Moldawer, L. L., Efron, P. A., & The Sepsis and Critical Illness Research Center Investigators. (2018). Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy. *Frontiers in Immunology*, 9, 595. <https://doi.org/10.3389/fimmu.2018.00595>
- Hu, Y., Shen, J., Liu, R., Feng, Z., Zhang, C., Ling, L., & Chen, L. (2018). Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: A systematic review and meta-analysis. *The International*

- Journal of Biological Markers*, 33(4), 372–378.
<https://doi.org/10.1177/1724600818799876>
- Jia, D., Nagaoka, Y., Katsumata, M., & Orsulic, S. (2018). Inflammation is a key contributor to ovarian cancer cell seeding. *Scientific Reports*, 8(1), 12394.
<https://doi.org/10.1038/s41598-018-30261-8>
- Jiménez-Sánchez, A., Cybulska, P., Mager, K. L., Koplev, S., Cast, O., Couturier, D.-L., Memon, D., Selenica, P., Nikolovski, I., Mazaheri, Y., Bykov, Y., Geyer, F. C., Macintyre, G., Gavarró, L. M., Drews, R. M., Gill, M. B., Papanastasiou, A. D., Sosa, R. E., Soslow, R. A., ... Miller, M. L. (2020). Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. *Nature Genetics*, 52(6), 582–593. <https://doi.org/10.1038/s41588-020-0630-5>
- Kobayashi, H. (2022). Recent advances in understanding the metabolic plasticity of ovarian cancer: A systematic review. *Heliyon*, 8(11), e11487.
<https://doi.org/10.1016/j.heliyon.2022.e11487>
- Komura, N., Mabuchi, S., Yokoi, E., Shimura, K., Kawano, M., Matsumoto, Y., & Kimura, T. (2019a). Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer. *International Journal of Gynecologic Cancer*, 29(6), 1057–1063. <https://doi.org/10.1136/ijgc-2019-000492>
- Komura, N., Mabuchi, S., Yokoi, E., Shimura, K., Kawano, M., Matsumoto, Y., & Kimura, T. (2019b). Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer. *Oncotarget*, 10(38), 3605–3613.
<https://doi.org/10.18632/oncotarget.26914>
- Kossaï, M., Leary, A., Scoazec, J.-Y., & Genestie, C. (2018). Ovarian cancer: A heterogeneous disease. *Pathobiology*, 85(1–2), 41–49.
- Koushik, A., Grundy, A., Abrahamowicz, M., Arseneau, J., Gilbert, L., Gotlieb, W. H., Lacaille, J., Mes-Masson, A.-M., Parent, M.-É., & Provencher, D. M. (2017). Hormonal and reproductive factors and the risk of ovarian cancer. *Cancer Causes & Control*, 28(5), 393–403.
- Kroeger Jr, P. T., & Drapkin, R. (2017). Pathogenesis and heterogeneity of ovarian cancer. *Current Opinion in Obstetrics & Gynecology*, 29(1), 26.
- Kurnit, K. C., Fleming, G. F., & Lengyel, E. (2021). Updates and new options in advanced epithelial ovarian cancer treatment. *Obstetrics and Gynecology*, 137(1), 108.
- La Vecchia, C. (2017). Ovarian cancer: Epidemiology and risk factors. *European Journal of Cancer Prevention*, 26(1), 55–62.
- Langdon, S. P., Herrington, C. S., Hollis, R. L., & Gourley, C. (2020). Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. *Cancers*, 12(6), 1647. <https://doi.org/10.3390/cancers12061647>
- Leone, R. D., & Powell, J. D. (2020). Metabolism of immune cells in cancer. *Nature Reviews Cancer*, 20(9), 516–531.
- Lheureux, S., Braunstein, M., & Oza, A. M. (2019). Epithelial ovarian cancer: Evolution of management in the era of precision medicine. *CA: A Cancer Journal for Clinicians*, 69(4), 280–304.

- Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019). Epithelial ovarian cancer. *The Lancet*, 393(10177), 1240–1253.
- Li, D., Yuan, X., Liu, J., Li, C., & Li, W. (2018). Prognostic value of prognostic nutritional index in lung cancer: A meta-analysis. *Journal of Thoracic Disease*, 10(9), 5298–5307. <https://doi.org/10.21037/jtd.2018.08.51>
- Li, X., Liu, Y., Zheng, S., Zhang, T., Wu, J., Sun, Y., Zhang, J., & Liu, G. (2021). Role of exosomes in the immune microenvironment of ovarian cancer (Review). *Oncology Letters*, 21(5), 377. <https://doi.org/10.3892/ol.2021.12638>
- Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z., & Telleria, C. (2019). High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. *International Journal of Molecular Sciences*, 20(4), 952. <https://doi.org/10.3390/ijms20040952>
- Liu, Y. L., Filippova, O. T., Zhou, Q., Iasonos, A., Chi, D. S., Zivanovic, O., Sonoda, Y., Gardner, G. J., Broach, V. A., O’Cearbhaill, R. E., Konner, J. A., Aghajanian, C., Long Roche, K., & Tew, W. P. (2020). Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. *Journal of Gynecologic Oncology*, 31(1), e17. <https://doi.org/10.3802/jgo.2020.31.e17>
- Loret, N., Denys, H., Tummers, P., & Berx, G. (2019). The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. *Cancers*, 11(6), 838. <https://doi.org/10.3390/cancers11060838>
- Lu, H.-M., Li, S., Black, M. H., Lee, S., Hoiness, R., Wu, S., Mu, W., Huether, R., Chen, J., Sridhar, S., Tian, Y., McFarland, R., Dolinsky, J., Tippin Davis, B., Mexal, S., Dunlop, C., & Elliott, A. (2019). Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing. *JAMA Oncology*, 5(1), 51. <https://doi.org/10.1001/jamaoncol.2018.2956>
- Macpherson, A. M., Barry, S. C., Ricciardelli, C., & Oehler, M. K. (2020). Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. *Journal of Clinical Medicine*, 9(9), 2967. <https://doi.org/10.3390/jcm9092967>
- Mallen, A. R., Townsend, M. K., & Tworoger, S. S. (2018). Risk Factors for Ovarian Carcinoma. *Hematology/Oncology Clinics of North America*, 32(6), 891–902. <https://doi.org/10.1016/j.hoc.2018.07.002>
- Mallen, A., Soong, T. R., Townsend, M. K., Wenham, R. M., Crum, C. P., & Tworoger, S. S. (2018). Surgical prevention strategies in ovarian cancer. *Gynecologic Oncology*, 151(1), 166–175. <https://doi.org/10.1016/j.ygyno.2018.08.005>
- Mallen, A., Todd, S., Robertson, S. E., Kim, J., Sehovic, M., Wenham, R. M., Extermann, M., & Chon, H. S. (2021). Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. *Gynecologic Oncology*, 161(3), 693–699. <https://doi.org/10.1016/j.ygyno.2021.03.008>

- Matsuo, K., Machida, H., Mandelbaum, R. S., Grubbs, B. H., Roman, L. D., Sood, A. K., & Gershenson, D. M. (2019). Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. *Gynecologic Oncology*, 153(2), 230–237.
- Matz, M., Coleman, M. P., Sant, M., Chirlaque, M. D., Visser, O., Gore, M., & Allemani, C. (2017). ‘The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)’, *Gynecologic Oncology*, 144(2), pp. 405–413. doi:10.1016/j.ygyno.2016.10.019.
- McKelvey, K. J., Hudson, A. L., Back, M., Eade, T., & Diakos, C. I. (2018). Radiation, inflammation and the immune response in cancer. *Mammalian Genome*, 29(11–12), 843–865. <https://doi.org/10.1007/s00335-018-9777-0>
- McMullen, M., Karakasis, K., Rottapel, R., & Oza, A. M. (2021). Advances in ovarian cancer, from biology to treatment. *Nature Cancer*, 2(1), 6–8. <https://doi.org/10.1038/s43018-020-00166-5>
- McSharry, V., Glennon, K., Mullee, A., & Brennan, D. (2021). The impact of body composition on treatment in ovarian cancer: A current insight. *Expert Review of Clinical Pharmacology*, 14(9), 1065–1074. <https://doi.org/10.1080/17512433.2021.1937125>
- Ménétrier-Caux, C., Ray-Coquard, I., Blay, J.-Y., & Caux, C. (2019). Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: An opportunity for combination with Cytokines? *Journal for ImmunoTherapy of Cancer*, 7(1), 85. <https://doi.org/10.1186/s40425-019-0549-5>
- Mengqin, Z., Yalin, H., Xing, L., Ya, L., Yalin, T., Xin, D., & Jianhua, R. (2024). ‘Trends in nutritional status and factors affecting prognostic nutritional index in ovarian cancer patients during chemotherapy: a prospective longitudinal study based on generalized estimating equations’, *Supportive Care in Cancer*, 32(3), p. 191. doi:10.1007/s00520-024-08384-8.
- Menon, U., Karpinskyj, C., & Gentry-Maharaj, A. (2018). Ovarian Cancer Prevention and Screening. *Obstetrics & Gynecology*, 131(5), 909–927. <https://doi.org/10.1097/AOG.0000000000002580>
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: Epidemiology and risk factors. *International Journal of Women’s Health*, 11, 287.
- Moro-García, M. A., Mayo, J. C., Sainz, R. M., & Alonso-Arias, R. (2018). Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes. *Frontiers in Immunology*, 9, 339. <https://doi.org/10.3389/fimmu.2018.00339>
- Morton, M., Patterson, J., Sciuva, J., Perni, J., Backes, F., Nagel, C., O’Malley, D. M., & Chambers, L. M. (2023). Malnutrition, sarcopenia, and cancer cachexia in gynecologic cancer. *Gynecologic Oncology*, 175, 142–155.
- Muthmainnah, P.R., Syahril, E., Rahmawati, Nulanda, M., & Dewi, A. S. (2023). ‘Karakteristik Penderita Kanker Ovarium di RS Ibnu Sina Makassar’, *Fakumi Medical Journal*, 3(7), pp. 499–507.

- Nazemi, M., & Rainero, E. (2020). Cross-Talk Between the Tumor Microenvironment, Extracellular Matrix, and Cell Metabolism in Cancer. *Frontiers in Oncology*, 10, 239. <https://doi.org/10.3389/fonc.2020.00239>
- Ning, F., Cole, C. B., & Annunziata, C. M. (2021). Driving Immune Responses in the Ovarian Tumor Microenvironment. *Frontiers in Oncology*, 10, 604084. <https://doi.org/10.3389/fonc.2020.604084>
- Niu, Z. and Yan, B. (2023) ‘Prognostic and clinicopathological effect of the prognostic nutritional index (PNI) in patients with cervical cancer: a meta-analysis’, *Annals of Medicine*, 55(2). doi:10.1080/07853890.2023.2288705.
- Orlandini, L., Nestola, T., Colloca, G. F., Ferrini, A., & Cesari, M. (2020). The Frailty Index in older women with gynecological cancer. *Aging Clinical and Experimental Research*, 32, 1561–1565.
- Orr, B., & Edwards, R. P. (2018). Diagnosis and treatment of ovarian cancer. *Hematology/Oncology Clinics*, 32(6), 943–964.
- Ørskov, M., Iachina, M., Guldberg, R., Mogensen, O., & Nørgård, B. M. (2016). Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. *BMJ open*, 6(4), e010123.
- Ovarian Cancer Surgery Guidelines Advanced stage (provisional document) [Internet]. [cited 2025 Aug 14]. Available from: <https://www.esgo.org/media/2016/10/Ovarian-cancer-surgery-Guidelines-advanced-stages.pdf>
- Pae, M., Meydani, S.N. and Wu, D. (2012) ‘The Role of Nutrition in Enhancing Immunity in Aging’, *Aging and Disease*, 3(1), p. 91.
- Pagano, A. P., Ford, K. L., Porter Starr, K. N., Kiss, N., Steed, H., Kung, J. Y., Elango, R., & Prado, C. M. (2022). Energy Metabolism in Gynecological Cancers: A Scoping Review. *International Journal of Environmental Research and Public Health*, 19(11), 6419. <https://doi.org/10.3390/ijerph19116419>
- Pandey, G., Patel, B., Dave, P. S., Patel, S., Arora, R., & Parekh, C. (2020) ‘Prognostic Nutrition Index and Its Significance in Advanced Ovarian Cancer’, *Indian Journal of Gynecologic Oncology*, 18(3), p. 85. doi:10.1007/s40944-020-00435-2.
- Park, S. H., Lee, S., Song, J. H., Choi, S., Cho, M., Kwon, I. G., Son, T., Kim, H.-I., Cheong, J.-H., & Hyung, W. J. (2020). Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. *European Journal of Surgical Oncology*, 46(4), 620–625.
- Peres, L. C., Cushing-Haugen, K. L., Anglesio, M., Wicklund, K., Bentley, R., Berchuck, A., Kelemen, L. E., Nazeran, T. M., Gilks, C. B., & Harris, H. R. (2018). Histotype classification of ovarian carcinoma: A comparison of approaches. *Gynecologic Oncology*, 151(1), 53–60.
- Peres, L. C., Mallen, A. R., Townsend, M. K., Poole, E. M., Trabert, B., Allen, N. E., Arslan, A. A., Dossus, L., Fortner, R. T., & Gram, I. T. (2019). High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort ConsortiumC-

- Reactive Protein and Ovarian Cancer Risk. *Cancer Research*, 79(20), 5442–5451.
- Péus, D., Newcomb, N., & Hofer, S. (2013). Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. *BMC medical informatics and decision making*, 13, 1–7.
- Piao, J., Lee, E. J., & Lee, M. (2020). Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis. *Gynecologic Oncology*, 157(2), 542–548.
- Pin, F., Barreto, R., Kitase, Y., Mitra, S., Erne, C. E., Novinger, L. J., Zimmers, T. A., Couch, M. E., Bonewald, L. F., & Bonetto, A. (2018). Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. *Journal of Cachexia, Sarcopenia and Muscle*, 9(4), 685–700.
- Plett, H., Harter, P., Ataseven, B., Heitz, F., Prader, S., Schneider, S., Heikaus, S., Fisseler-Eckhoff, A., Kommoss, F., Lax, S. F., Staebler, A., Traut, A., & Du Bois, A. (2020). Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. *Gynecologic Oncology*, 157(2), 411–417. <https://doi.org/10.1016/j.ygyno.2020.02.007>
- Prat, J., D'Angelo, E., & Espinosa, I. (2018). Ovarian carcinomas: At least five different diseases with distinct histological features and molecular genetics. *Human Pathology*, 80, 11–27. <https://doi.org/10.1016/j.humpath.2018.06.018>
- Rahma, O. E., & Hodi, F. S. (2019). The Intersection between Tumor Angiogenesis and Immune Suppression. *Clinical Cancer Research*, 25(18), 5449–5457. <https://doi.org/10.1158/1078-0432.CCR-18-1543>
- Reid, F., Bhatla, N., Oza, A. M., Blank, S. V., Cohen, R., Adams, T., Benites, A., Gardiner, D., Gregory, S., Suzuki, M., & Jones, A. (2021). The World Ovarian Cancer Coalition Every Woman Study: Identifying challenges and opportunities to improve survival and quality of life. *International Journal of Gynecologic Cancer*, 31(2), 238–244. <https://doi.org/10.1136/ijgc-2019-000983>
- Renavikar, P. S., Chen, J., & Lele, S. M. (2023). Epithelial ovarian carcinoma—a perspective. *Journal of Histotechnology*, 46(2), 55–56.
- Rossi, J.-F., Lu, Z. Y., Massart, C., & Levon, K. (2021). Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer. *Frontiers in Immunology*, 12, 595722. <https://doi.org/10.3389/fimmu.2021.595722>
- Saed, G. M., Diamond, M. P., & Fletcher, N. M. (2017). Updates of the role of oxidative stress in the pathogenesis of ovarian cancer. *Gynecologic Oncology*, 145(3), 595–602.
- Savant, S. S., Sriramkumar, S., & O'Hagan, H. M. (2018). The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. *Cancers*, 10(8), 251.
- Savitri, I., & Askandar, B. (2021). The Role of Procalcitonin as a Prognostic Variable in Ovarian Cancer Patients at Dr. Soetomo General Hospital Surabaya. *Indonesian Journal of Cancer*, 15(3), 107–111.

- Schiessel, D. L., & Baracos, V. E. (2018). Barriers to cancer nutrition therapy: Excess catabolism of muscle and adipose tissues induced by tumour products and chemotherapy. *Proceedings of the Nutrition Society*, 77(4), 394–402. <https://doi.org/10.1017/S0029665118000186>
- Schuetz, P., SereS, D., Lobo, D. N., Gomes, F., Kaegi-Braun, N., & Stanga, Z. (2021) ‘Management of disease-related malnutrition for patients being treated in hospital’, *The Lancet*, 398(10314), pp. 1927–1938. doi:10.1016/S0140–6736(21)01451–3.
- Schüler-Toprak, S., Weber, F., Skrzypczak, M., Ortmann, O., & Treeck, O. (2018). Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer. *BMC Cancer*, 18(1), 981. <https://doi.org/10.1186/s12885-018-4898-0>
- Seol, A., Kim, S. I., & Song, Y. S. (2020). Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management. *Sports Medicine and Health Science*, 2(4), 202–210.
- Sharma, K., Mogensen, K. M., & Robinson, M. K. (2019). Pathophysiology of Critical Illness and Role of Nutrition. *Nutrition in Clinical Practice*, 34(1), 12–22. <https://doi.org/10.1002/ncp.10232>
- Sheinenzon, A., Shehadeh, M., Michelis, R., Shaoul, E., & Ronen, O. (2021). Serum albumin levels and inflammation. *International Journal of Biological Macromolecules*, 184, 857–862. <https://doi.org/10.1016/j.ijbiomac.2021.06.140>
- Shi, X., Lv, Y., Wang, P., Yang, X., & You, S. (2022). Analysis of the Correlation between Nutritional Status and Quality of Life of Patients with Gynaecological Ovarian Cancer during Postoperative Chemotherapy. *Journal of Oncology*, 2022, 1–9. <https://doi.org/10.1155/2022/9877354>
- Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, 70(1), 7–30. <https://doi.org/10.3322/caac.21590>
- Singh, N., Baby, D., Rajguru, J. P., Patil, P. B., Thakkannavar, S. S., & Pujari, V. B. (2019). Inflammation and Cancer. *Annals of African Medicine*, 18(3), 121–126. https://doi.org/10.4103/aam.aam_56_18
- Sköld, C., Koliadi, A., Enblad, G., Ståhlberg, K., & Glimelius, I. (2022). Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes. *International Journal of Cancer*, 150(5), 773–781.
- Smith-Bindman, R., Poder, L., Johnson, E., & Miglioretti, D. L. (2019). Risk of malignant ovarian cancer based on ultrasonography findings in a large unselected population. *JAMA Internal Medicine*, 179(1), 71–77.
- Soeters, P. B., Wolfe, R. R., & Shenkin, A. (2019). Hypoalbuminemia: Pathogenesis and clinical significance. *Journal of Parenteral and Enteral Nutrition*, 43(2), 181–193.
- Souza Cunha, M., Wiegert, E. V. M., Calixto-Lima, L., & Oliveira, L. C. (2018). Relationship of nutritional status and inflammation with survival in patients with advanced cancer in palliative care. *Nutrition*, 51–52, 98–103. <https://doi.org/10.1016/j.nut.2017.12.004>

- Stewart, C., Ralyea, C., & Lockwood, S. (2019). *Ovarian cancer: An integrated review*. 35(2), 151–156.
- Stewart, L. M., Spilsbury, K., Jordan, S., Stewart, C., Holman, C. D. J., Powell, A., Reekie, J., & Cohen, P. (2018). Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. *Cancer Epidemiology*, 55, 110–116. <https://doi.org/10.1016/j.canep.2018.05.011>
- Thomassin-Naggara, I., Daraï, E., Lécure, F., & Fournier, L. (2019). Diagnostic value of imaging (ultrasonography, doppler, CT, MR, PET-CT) for the diagnosis of a suspicious ovarian mass and staging of ovarian, tubal or primary peritoneal cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa. *Gynecologie, Obstetrique, Fertilité & Senologie*, 47(2), 123–133.
- Toufakis, V., Katuwal, S., Pukkala, E., & Tapanainen, J. S. (2021). Impact of parity on the incidence of ovarian cancer subtypes: a population-based case-control study. *Acta Oncologica*, 60(7), 850–855.
- Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019). Characteristics of in vivo model systems for ovarian cancer studies. *Diagnostics*, 9(3), 120.
- Wang, X., & Wang, Y. (2019). The prognostic nutritional index is prognostic factor of gynecological cancer: A systematic review and meta-analysis. *International Journal of Surgery*, 67, 79–86. <https://doi.org/10.1016/j.ijso.2019.05.018>
- Wendel, J., Wang, X., & Hawkins, S. (2018). The Endometriotic Tumor Microenvironment in Ovarian Cancer. *Cancers*, 10(8), 261. <https://doi.org/10.3390/cancers10080261>
- World Health Organization. Study on global ageing and adult health (SAGE) [Internet]. Geneva: World Health Organization; [cited 2025 Aug 14]. Available from: <https://www.who.int/data/data-collection-tools/study-on-global-ageing-and-adult-health>
- Wu, N.-Y. Y., Fang, C., Huang, H.-S., Wang, J., & Chu, T.-Y. (2020). Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. *Modern Pathology*, 33(1), 29–37. <https://doi.org/10.1038/s41379-019-0370-1>
- Xie, W., Sun, H., Li, X., Lin, F., Wang, Z., & Wang, X. (2021). Ovarian cancer: Epigenetics, drug resistance, and progression. *Cancer Cell International*, 21(1), 434. <https://doi.org/10.1186/s12935-021-02136-y>
- Yarmolinsky, J., Relton, C. L., Lophatananon, A., Muir, K., Menon, U., Gentry-Maharaj, A., Walther, A., Zheng, J., Fasching, P., Zheng, W., Yin Ling, W., Park, S. K., Kim, B.-G., Choi, J.-Y., Park, B., Davey Smith, G., Martin, R. M., & Lewis, S. J. (2019). Appraising the role of previously

- reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. *PLOS Medicine*, 16(8), e1002893. <https://doi.org/10.1371/journal.pmed.1002893>
- Ye, Y., Dai, Q., & Qi, H. (2021). A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer. *Cell Death Discovery*, 7(1), 1–11.
- Yoshikawa, N., Yoshida, K., Tamauchi, S., Ikeda, Y., Nishino, K., Niimi, K., Suzuki, S., Kikkawa, F., & Kajiyama, H. (2020). The Preoperative Prognostic Nutritional Index for the Prediction of Outcomes in Patients with Early-Stage Ovarian Clear Cell Carcinoma. *Scientific Reports*, 10(1), 7135. <https://doi.org/10.1038/s41598-020-64171-5>
- Yousefi, M., Dehghani, S., Nosrati, R., Ghanei, M., Salmaninejad, A., Rajaie, S., Hasanzadeh, M., & Pasdar, A. (2020). Current insights into the metastasis of epithelial ovarian cancer—Hopes and hurdles. *Cellular Oncology*, 43(4), 515–538. <https://doi.org/10.1007/s13402-020-00513-9>
- Zhang, W., Ye, B., Liang, W., & Ren, Y. (2017). ‘Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer’, *Scientific Reports*, 7(1), p. 9548. doi:10.1038/s41598-017-10328-8.
- Zheng, G., Yu, H., Kanerva, A., Försti, A., Sundquist, K., & Hemminki, K. (2018). Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLOS ONE*, 13(10), e0205000. <https://doi.org/10.1371/journal.pone.0205000>
- Zhou, J., Wu, S.-G., Wang, J., Sun, J.-Y., He, Z.-Y., Jin, X., & Zhang, W.-W. (2018). The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer. *Frontiers in Oncology*, 8, 577.